Blueprint Medicines Corp (BPMC)
94.15
-2.47
(-2.56%)
USD |
NASDAQ |
Nov 22, 16:00
94.20
+0.05
(+0.05%)
After-Hours: 20:00
Blueprint Medicines Enterprise Value: 5.633B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 5.633B |
| November 21, 2024 | 5.790B |
| November 20, 2024 | 5.675B |
| November 19, 2024 | 5.662B |
| November 18, 2024 | 5.381B |
| November 15, 2024 | 5.286B |
| November 14, 2024 | 5.729B |
| November 13, 2024 | 5.807B |
| November 12, 2024 | 5.790B |
| November 11, 2024 | 5.997B |
| November 08, 2024 | 6.058B |
| November 07, 2024 | 6.093B |
| November 06, 2024 | 5.981B |
| November 05, 2024 | 5.849B |
| November 04, 2024 | 5.489B |
| November 01, 2024 | 5.414B |
| October 31, 2024 | 5.212B |
| October 30, 2024 | 5.321B |
| October 29, 2024 | 4.950B |
| October 28, 2024 | 4.910B |
| October 25, 2024 | 4.886B |
| October 24, 2024 | 4.925B |
| October 23, 2024 | 5.008B |
| October 22, 2024 | 5.139B |
| October 21, 2024 | 5.085B |
| Date | Value |
|---|---|
| October 18, 2024 | 5.110B |
| October 17, 2024 | 5.110B |
| October 16, 2024 | 5.321B |
| October 15, 2024 | 5.311B |
| October 14, 2024 | 5.278B |
| October 11, 2024 | 5.288B |
| October 10, 2024 | 5.171B |
| October 09, 2024 | 5.210B |
| October 08, 2024 | 5.203B |
| October 07, 2024 | 5.320B |
| October 04, 2024 | 5.275B |
| October 03, 2024 | 5.241B |
| October 02, 2024 | 5.412B |
| October 01, 2024 | 5.363B |
| September 30, 2024 | 5.522B |
| September 27, 2024 | 5.486B |
| September 26, 2024 | 5.265B |
| September 25, 2024 | 5.134B |
| September 24, 2024 | 5.342B |
| September 23, 2024 | 5.328B |
| September 20, 2024 | 5.431B |
| September 19, 2024 | 5.384B |
| September 18, 2024 | 5.282B |
| September 17, 2024 | 5.103B |
| September 16, 2024 | 5.090B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.458B
Minimum
Nov 09 2022
7.235B
Maximum
Jul 16 2024
3.891B
Average
3.678B
Median
Sep 16 2020
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.91B |
| Regeneron Pharmaceuticals Inc | 73.29B |
| NovaBay Pharmaceuticals Inc | 2.608M |
| Palatin Technologies Inc | 16.38M |
| iBio Inc | 14.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.28M |
| Revenue (Quarterly) | 128.18M |
| Total Expenses (Quarterly) | 177.16M |
| EPS Diluted (Quarterly) | -0.89 |
| Gross Profit Margin (Quarterly) | 98.49% |
| Profit Margin (Quarterly) | -43.90% |
| Earnings Yield | -2.24% |
| Normalized Earnings Yield | -5.126 |